MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION

  • Authors:
    • P TAGLIAFERRI
    • E MATANO
    • A REA
    • M FAMIANI
    • F CIARDIELLO
    • G TORTORA
    • V MONTESARCHIO
    • A MORABITO
    • M CARAGLIA
    • M DELAURENTIIS
    • S DEPLACIDO
    • G PALMIERI
    • AR BIANCO
  • View Affiliations

  • Published online on: May 1, 1995     https://doi.org/10.3892/or.2.3.365
  • Pages: 365-368
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The antitumor activity and toxicity profile of a new therapeutic combination was investigated for patients with non-Hodgkin's lymphoma (NHL). The regimen consisted of mitoxantrone (10 mg/m(2)/day by intravenous (i.v.) bolus injection on day 1), etoposide (100 mg by 24 hours continuous i.v. infusion on days 1, 2, 3) and bleomycin (4 mg by i.v. bolus injection on day 1 followed by 24 hours continuous i.v. infusion at 4 mg/m2/day dose on days 1, 2, 3) (MEB). MEB chemotherapy was administered to 22 patients affected by intermediate/high grade or clinically symptomatic low grade NHL who were considered non-elegible for standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy. Major responses were achieved in 11/22 (50%) patients with 5 (23%) complete responses. Grade 3-4 neutropenia occurred in 59% of patients. The results of this study demonstrate that MEB chemotherapy possesses good antitumor activity and a manageable toxicity in a prognostically unfavourable subset of lymphoma patients.

Related Articles

Journal Cover

May 1995
Volume 2 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
TAGLIAFERRI P, MATANO E, REA A, FAMIANI M, CIARDIELLO F, TORTORA G, MONTESARCHIO V, MORABITO A, CARAGLIA M, DELAURENTIIS M, DELAURENTIIS M, et al: MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION. Oncol Rep 2: 365-368, 1995
APA
TAGLIAFERRI, P., MATANO, E., REA, A., FAMIANI, M., CIARDIELLO, F., TORTORA, G. ... BIANCO, A. (1995). MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION. Oncology Reports, 2, 365-368. https://doi.org/10.3892/or.2.3.365
MLA
TAGLIAFERRI, P., MATANO, E., REA, A., FAMIANI, M., CIARDIELLO, F., TORTORA, G., MONTESARCHIO, V., MORABITO, A., CARAGLIA, M., DELAURENTIIS, M., DEPLACIDO, S., PALMIERI, G., BIANCO, A."MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION". Oncology Reports 2.3 (1995): 365-368.
Chicago
TAGLIAFERRI, P., MATANO, E., REA, A., FAMIANI, M., CIARDIELLO, F., TORTORA, G., MONTESARCHIO, V., MORABITO, A., CARAGLIA, M., DELAURENTIIS, M., DEPLACIDO, S., PALMIERI, G., BIANCO, A."MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION". Oncology Reports 2, no. 3 (1995): 365-368. https://doi.org/10.3892/or.2.3.365